Will Broad Zovegalisib Breast Cancer Data Reshape Relay Therapeutics' (RLAY) Targeted Oncology Narrative? [Yahoo! Finance]
Relay Therapeutics, Inc. (RLAY)
Company Research
Source: Yahoo! Finance
meaningful progression-free survival and response rates in heavily pretreated patients with PI3Ka-mutated, HR+/HER2- advanced breast cancer, with mostly low-grade, manageable side effects. A striking insight is that zovegalisib's activity appeared broadly consistent even in harder-to-treat groups, such as patients with prior SERD exposure or baseline ESR1 mutations, which could broaden its potential clinical role if future trials confirm these findings. Against this backdrop and recent share price gains, we'll examine how the broad efficacy across prior-treatment subgroups shapes Relay Therapeutics' investment narrative. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit To own Relay Therapeutics, you have to believe its precision oncology platform can translate strong early signals into approved drugs before cash and patience run thin. The new zovegalisib data slots directly into that thesis: consistent prog
Show less
Read more
Impact Snapshot
Event Time:
RLAY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLAY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLAY alerts
High impacting Relay Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLAY
News
- Relay Therapeutics (RLAY): Revisiting Valuation After a Sharp Rebound in 2024 [Yahoo! Finance]Yahoo! Finance
- Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 [Yahoo! Finance]Yahoo! Finance
- Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025GlobeNewswire
- Relay Therapeutics (NASDAQ:RLAY) was upgraded by analysts at Wells Fargo & Company to an "overweight" rating.MarketBeat
- Will Relay Therapeutics (RLAY) Board Additions Signal a Shift in Commercialization Strategy? [Yahoo! Finance]Yahoo! Finance
RLAY
Earnings
- 11/6/25 - Miss
RLAY
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/6/25 - Form 4
- 11/6/25 - Form 4
- RLAY's page on the SEC website